Kigali: The African Medicines Agency and the European Medicines Agency have issued joint guidance on the clinical development of a Bundibugyo Ebola vaccine, giving developers a common route to trials during an emergency that has spread beyond the Democratic Republic of the Congo. The two agencies published the position paper on 23 October 2026 through the EMA’s Emergency Task Force and the AMA.
The EMA cites an ongoing public health emergency in the DRC, with cases also detected in Uganda, Kenya and Nigeria. The paper does not give case counts, so this article does not either. It follows a scientific consultation hosted by the AMA, the EMA and the World Health Organization on 24 August 2026, and it covers viral-vectored and mRNA vaccine platforms.
Unlike Zaire Ebola, Bundibugyo virus has no licensed vaccine, so any Bundibugyo Ebola vaccine must start from early trials. The guidance sets out how. For preclinical work, repeat-dose toxicity studies may be deferred or waived for platforms with well-characterised data, such as VSV, ChAdOX1 and mRNA, though immunogenicity data in small rodents are still needed. Challenge studies in macaques are called the gold standard but are not required to begin phase I and II trials. They should be ready before ring vaccination trials, and ferrets may be accepted in some cases.
For any Bundibugyo Ebola vaccine, early trials should enrol healthy adults, ideally in Africa, using single-dose vaccines and a placebo control. The primary endpoint is safety, and the paper suggests about 20 to 30 subjects per arm. Antibody responses are secondary endpoints, measured at day 14 and day 28 after the last dose and again at six and twelve months. Trials in children should start as soon as four-week adult data are available, with at least 20 children per dose in each age band.
The pivotal design for a Bundibugyo Ebola vaccine is a randomised ring trial. Contacts of confirmed cases are identified and randomised to immediate vaccination or placebo, and placebo recipients may receive the vaccine about 28 days later if this does not affect the primary endpoint. Several candidates can share a single platform trial with concurrent controls. Pregnant women may join if platform data show no harm to the fetus, and the design can move to an active comparator if an effective vaccine is established.
Regulators carry part of the burden for any Bundibugyo Ebola vaccine. Developers are told to engage early with the AMA, African national regulators and the EMA, and national authorities are asked to accelerate regulatory and ethics review. A single independent monitoring committee is recommended across trials.
For civil protection planners, the guidance shows how preparedness works in practice. Agreed endpoints, shared platforms and early regulatory contact shorten the time between an outbreak and a trial that produces usable evidence. Humanitarian agencies and health ministries in affected countries will depend on that speed.
The paper does not name candidate products, and no Bundibugyo Ebola vaccine has yet shown efficacy in people. What the agencies have done is remove uncertainty about the rules, so that the first credible candidate can reach the field without waiting for regulators to decide how to judge it.
